Intensive chemotherapy followed by autologous bone marrow transplantation (ABMT) is now widely used as early consolidation therapy for stage IV neuroblastoma in children over one year of age (August et al., 1984; Philip et al., 1987; Graham-Pole et al., 1984; Pritchard et al., 1982; Hartmann et al., 1987; D'Angio et al., 1985) . After induction therapy, at least 50% of such children fail to achieve complete remission and receive their bone marrow graft in partial remission. In these patients, scanty neuroblastoma cells may be detected in the marrow by the analysis of multiple biopsies although aspirates were often negative Favrot & Herve, 1987; Franklin & Pritchard, 1983; Borstrom et al., 1985) ; this may be due to lack of sensitivity of cytological detection methods or to the fact that these clumps of neuroblastoma cells are not sucked out. One of the major issues in the treatment of neuroblastoma is thus to know whether bone marrow harvested for an autograft contains malignant cells or not, and whether these cells can be eliminated by an in vitro purging procedure before the graft is reinjected. It is therefore of major importance to develop accurate methods to detect and quantify rare neuroblasts in the marrow to be used for autograft. Neuroblasts have very low clonogenic efficiency in culture, however; cytogenetic analysis is not useful in detecting very small numbers of neuroblasts, and molecular biology techniques do not yet permit detection of less than 2% malignant cells (Favrot & Herve, 1987) . In theory, immunological analysis should be the optimal method of detection since monoclonal antibodies which recognise neuroblasts are now available (Allan et al., 1983; Kemshead et al., 1983; Favrot et al., 1988; Cheung et al., 1986; Evans et al., 1984 (Philip et al., 1987a,b) , or patients referred from other centres for inclusion in the Centre Leon Berard pilot study of double ABMT . In the first group marrow was harvested after four to seven courses of induction therapy as previously described (Philip et al., 1987a) . In the second group, patients usually received two courses of VP16 and CDDP before marrow harvesting (Philip et al., 1987b .
Morphological examination of the marrow was performed as previously described . At the time of marrow harvesting under general anaesthesia, four marrow biopsies and four aspirates were performed in posterior and anterior iliac crests. Formalin-fixed trephines were analysed with conventional haematein phloxin safran staining; two spread films from each marrow aspirate were stained by May Grumwald Giemsa.
Harvested marrow was collected on citrate phosphate dextrose; mononuclear marrow cells were obtained by Ficoll separation on a blood cell processor (COBE 2991). Five million mononuclear marrow cells were taken for immunological analysis before purging, and the harvested marrow was then purged by an immunomagnetic depletion (IMD) procedure using five monoclonal antibodies (i.e. UJ13A, H-1, UJ127-11, UJ181-4 and aThy 1), as previously described Trealeaven et al., 1984) . A further five million mononuclear marrow cells were then taken for immunological analysis after purging.
Normal bone marrow samples After informed consent, according to the Centre Leon Berard ethical rules, marrow samples obtained under general anaesthesia from non-cancer patients or regenerating marrow samples from patients with neuroblastoma or malignant lymphoma in complete remission were used as control for the immunological analysis (see below).
Immunological analysis UJ13A and HI1 MoAbs (kindly provided by J. Kemshead) and S-L 11.14 (kindly provided by J.C. Laurent) recognise antigens expressed by cells of neuroectodermal origin (11) (12) (13) (14) . These IgG antibodies strongly react with 90% of our patients' tumour samples (either neuroblastoma cells in heavily involved marrow, at diagnosis or relapse, or primary tumours taken at surgery). The UJ13A and Hi 1 MoAbs are included in the cocktail used for the purging procedure whereas 11.14 was selected in such study as a third marker which does not interfere with the purging cocktail. NKHia (Coulter, France) is an IgM reagent claimed to be relatively specific for NK cells (Hercend et al., 1983 ). An IgM antipanleucocyte MoAb (recognising CD45) was kindly provided by G. Janossy. (Warnke et al., 1983; Maritaz et al., 1988 Limit of detection The methods were shown to enable the detection of as few as 10-5 neuroblastoma cells in the marrow if 3 x 106 cells are analysed in two-colour fluorochrome labelling and six smears in alkaline phosphatase (blind study) (Maritaz et al., 1988) .
Results
Reactivity of 11.14, UJ13A and Hi1 with normal haematopoietic cells Ten marrow samples from healthy donors were analysed by the two-colour fluorochrome labelling; all three MoAbs, used as single reagent, stained less than 1% haematopoietic cells. In patients treated for malignant lymphoma and in complete remission, samples of regenerating marrow taken after chemotherapy contained up to 10% marrow cells stained with one or the other reagent. Such non-specific staining was also observed in our neuroblastoma patients in complete remission. Two-colour fluorochrome labelling with an antipanleucocyte monoclonal antibody on normal marrow or marrow from patients with malignant lymphoma in remission enabled us to confirm that these positive isolated cells were indeed of haematopoietic origin. Similarly, double labelling with NKH1, on those samples proved that those rare lymphoid cells reacting with anti-NBL markers belonged to the natural killer cell subpopulation. In the results described below, all samples were analysed by twocolour fluorochrome labelling.
Comparison of the morphological detection of bone marrow micrometastasis with the immunological detection of malignant cells in the autograft: 34 cases Samples for morphological analysis of the marrow and immunological analysis of the autograft were taken on the same day during the marrow harvest surgical procedure. Four biopsies and eight spread films (two per aspiration site) were analysed for each patient. Three million cells were analysed in two-colour fluorochrome labelling and six smears (6 x 104 cells per smear) were analysed by alkaline phosphatase immunostaining before and after the purging procedure. (see Table I ).
In 16 cases, both morphological examination of the marrow and immunological analysis of harvested marrow cells were normal. In 18 cases, malignant cells were detected in the marrow by one or the other method as detailed below.
In three cases, biopsies, aspirates and immunological analysis were positive; two to three of the eight morphological specimens contained one or two clumps of neuroblastoma cells and the immunological analysis permitted to detect from 10-4 to 1% residual malignant cells in the three corresponding autografts before purging.
In 12 cases, biopsies were positive but aspirates were negative; three patients had only one positive biopsy but three patients had three to four positive biopsies with one or two detectable clumps in each. Before the purging procedure, the immunological analysis permitted to detect 10-3 to 10-5 residual neuroblastoma cells in the autograft of only six of these patients.
In one case, the four biopsies were negative but the aspirates contained rare atypical lymphoid-like malignant cells; the immunological analysis of the autograft confirmed the presence of 1% malignant cells.
In two cases the four biopsies and four aspirates were completely negative, but clumps of malignant cells were detected in the autograft by the two-colour fluorochrome labelling, the contamination being 1 NBL cell in 105 marrow cells.
Finally, when marrows were analysed after the purging procedure they did not contain any residual neuroblastoma cell detectable by immunological analysis.
The combination of these two immunological methods enables detection of one NBL cell in 105 marrow cells in the autograft. Particularly in 11 of the 12 cases of contaminated autografts, malignant cells were detectable by the two-colour fluorochrome labelling; alkaline phosphatase immunostaining was positive in only five cases, one only with negative immunofluorescence and four with concomitant positive immunofluorescence.
Discussion
In this series of 34 consecutive neuroblastoma patients entered in an AMBT programme, 16 had marrow micrometastases detectable by cytohistological examination of four trephine biopsies and four aspirates on the day of marrow harvest; in agreement with our previous results, biopsies were more accurate than aspirates in detecting these rare neuroblasts. The marrow infiltration by neuroblastoma cells is very focal and biopsies or aspirates only explore four iliac sites whereas the marrow harvested for an autograft is taken from the entire iliac site. The immunological analysis of the cells from the whole harvested marrow enabled us to demonstrate that the autograft was contaminated by neuroblasts in 12 of the 34 cases analysed, 10 with concomitant positive biopsies and/or aspirates, and two with negative biopsies and aspirates. The autograft contamination could be quantified and ranged from 10-2 to 10-5 malignant cells; after ex vivo purging procedure, none of the autografts contained residual malignant cells detectable by immunological analysis; less than 10-5 neuroblasts were thus potentially left when the marrow was reinjected to the patient. In the seven cases in which one of the biopsies was positive and malignant cells were undetectable in the harvested marrow by immunological analysis, the autograft contained less than 10-5 NBL cells or could even be normal if very focal clumps of malignant cells failed to be aspirated during the harvesting procedure.
The great sensitivity of the immunological detection is due, first, to the Ficoll separation of the mononuclear cell population before the analysis. Separation of the marrow cells, either on a Ficoll gradient or on a discontinuous sedimentation gradient, had been reported to enrich the marrow population with malignant cells, by eliminating red cells and granulocytes, and to improve the examination (Maritaz et al., 1988; Bayle et al., 1985; Hunter et al., 1987) . The sensitivity of the method described here is due, secondly, to the objective characterisation of malignant cells. The twocolour fluorochrome labelling method enables an objective distinction to be made between the few lymphocytes which stain with both the anti-panleucocyte and the antineuroblastoma antibodies, and isolated neuroblastoma cells which are panleucocyte negative. Similarly, the immunoalkaline phosphatase staining permits identification of pseudolymphoid neuroblasts by their membrane positivity. Finally, the number of cells analysed for each case in this study (3 x 106 in two-colour fluorochrome labelling and 6 x 105 in alkaline phosphatase) allows detection down to 10-5 neuroblasts by immunological analysis. In this context, two-colour fluorochrome labelling offers several advantages when compared to alkaline phosphatase staining. In the first method, the processing of 3 x 106 mononuclear cells only requires 90 min once the marrow has been harvested and their analysis on three different slides takes 30min. Immunostaining and analysis of six smears by the alkaline phosphatase method usually takes 4-5 h and consequently limits the total number of mononuclear cells to be analysed. The greater sensitivity of two-colour fluorochrome labelling is due to the larger number of cells analysed. Two-colour fluorochrome labelling thus appears, both for its sensitivity and its simplicity, as an optimal method to develop routinely in a laboratory involved in clinical programmes in ABMT. The method can be easily adjusted to the analysis of the marrow in various solid tumours. In small cell lung cancer, the three markers used in this study (UJ13A, Hi 1 and 11.14) strongly react with the malignant cells and the method of detection is strictly similar; in other tumours such as breast cancer, relevant markers of the malignant cells are available.
For clinicians, such an analysis clearly selects a group of patients whose autograft is contaminated with malignant cells and for whom the use of a purging procedure is largely justified. In addition, the immunological analysis enables the efficiency of clinical purging procedures to be checked and allows the elimination of malignant cells to be quantified. Such data are of particular interest in a disease such as neuroblastoma in which two patients out of three never reach complete remission and are thus autografted in partial remission. To determine whether relapses are due to the failure of high dose chemotherapy or to the reinjection of malignant cells is a prerequisite in the improvement or modification of therapeutic protocols.
